Prostein Expression on Circulating Tumor Cells As a Prognostic Marker in Metastatic Castration-resistant Prostate Cancer

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2023 Dec 6

PMID 38057610

Authors

Zhenchao Zhang

Rui Luo

William K Kelly

Joshua Chen

Shane Donahue

Kevan Ip

Nathan R Handley

William J Tester

Miranda L Tsang

Felix J Kim

Ronald Myers

Grace Lu-Yao

Jian Gu

Jianqing Lin

Bingshan Li

Chun Wang

Hushan Yang

Affiliations

Soon will be listed here.

Abstract

Background: Identification of emerging molecular biomarkers on circulating tumor cells (CTCs) represents an attractive feature of liquid biopsy that facilitates precision and tailored medicine in the management of metastatic castration-resistant prostate cancer (mCRPC). Prostein is an androgen-regulated transmembrane protein with high prostate specificity. Prostein-positive circulating tumor cell (CTC) was recently suggested to have diagnostic potential; however, no study has been conducted to evaluate its prognostic value in mCRPC.

Methods: CTCs from mCRPC patients were enumerated using the CellSearch System. Prostein-positive CTCs were identified by immunostaining results. The relationships between prostein expression on CTCs and PSA response rate, PSA progression-free survival (PSA-PFS), radiographic progression-free survival (PFS), and overall survival (OS) were tested by Fisher's exact test or evaluated using Kaplan-Meier and multivariate Cox analyses.

Results: Prostein-positive CTCs were identified in 31 of 87 baseline samples from mCRPC patients and 16 of 51 samples collected at the first follow-up visit. PSA response rates were significantly lower in baseline prostein-positive patients (0%, 0/31) than in prostein-negative patients (19.6%, 11/56) (p = 0.007). The 31 prostein-positive patients had significantly shorter PSA-PFS (p < 0.001), radiographic PFS (p < 0.001), and OS (p = 0.018), compared to the 56 prostein-negative patients at baseline. The association with PSA-PFS maintained its significance (p = 0.028) in multivariate analyses. Analyzing prostein expression at the first follow-up as well as the conversion of prostein expression from baseline to follow-up samples not only confirmed the association with PSA-PFS, but also demonstrated prognostic significance with OS.

Conclusion: Our study provides the first evidence to support the potential of prostein expression on CTCs to serve as a novel prognostic marker in mCRPC patients. Future large-scale prospective studies are needed to validate our findings.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Lowrance W, Murad M, Oh W, Jarrard D, Resnick M, Cookson M . Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018; 200(6):1264-1272. DOI: 10.1016/j.juro.2018.07.090. View

Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto B, Palmieri A . Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives. Cancers (Basel). 2022; 14(13). PMC: 9265840. DOI: 10.3390/cancers14133272. View

Trujillo B, Wu A, Wetterskog D, Attard G . Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022; 127(8):1394-1402. PMC: 9553885. DOI: 10.1038/s41416-022-01881-9. View

Tulpule V, Morrison G, Falcone M, Quinn D, Goldkorn A . Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Curr Oncol Rep. 2022; 24(10):1287-1298. PMC: 9474724. DOI: 10.1007/s11912-022-01278-0. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

Goldkorn A, Ely B, Quinn D, Tangen C, Fink L, Xu T . Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(11):1136-42. PMC: 3970171. DOI: 10.1200/JCO.2013.51.7417. View

Heller G, McCormack R, Kheoh T, Molina A, Smith M, Dreicer R . Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2017; 36(6):572-580. PMC: 5815402. DOI: 10.1200/JCO.2017.75.2998. View

10.

Wang C, Zhang Z, Chong W, Luo R, Myers R, Gu J . Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021; 13(2). PMC: 7828213. DOI: 10.3390/cancers13020268. View

11.

van der Toom E, Axelrod H, de la Rosette J, de Reijke T, Pienta K, Valkenburg K . Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol. 2018; 16(1):7-22. PMC: 6324967. DOI: 10.1038/s41585-018-0119-5. View

12.

Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-38. PMC: 4201502. DOI: 10.1056/NEJMoa1315815. View

13.

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y . Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol. 2017; 35(19):2149-2156. PMC: 5493048. DOI: 10.1200/JCO.2016.70.1961. View

14.

Nagaya N, Nagata M, Lu Y, Kanayama M, Hou Q, Hotta Z . Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One. 2020; 15(1):e0226219. PMC: 6984691. DOI: 10.1371/journal.pone.0226219. View

15.

Francolini G, Loi M, Ciccone L, Detti B, Di Cataldo V, Pinzani P . Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275). Med Oncol. 2022; 39(8):119. DOI: 10.1007/s12032-022-01756-2. View

16.

Nuhn P, de Bono J, Fizazi K, Freedland S, Grilli M, Kantoff P . Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2018; 75(1):88-99. DOI: 10.1016/j.eururo.2018.03.028. View

17.

Xu J, Kalos M, Stolk J, Zasloff E, Zhang X, Houghton R . Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001; 61(4):1563-8. View

18.

Sheridan T, Herawi M, Epstein J, Illei P . The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007; 31(9):1351-5. DOI: 10.1097/PAS.0b013e3180536678. View

19.

Ried K, Tamanna T, Matthews S, Eng P, Sali A . New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers. Front Oncol. 2020; 10:582. PMC: 7192049. DOI: 10.3389/fonc.2020.00582. View

20.

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View